Anne Kasus-Jacobi, Ph.D.

Associate Professor

Pharmaceutical Sciences

Phone (405) 271-1484

Alt Phone (405) 637-3432

Fax (405) 271-7505

Office CPB 255

Email Anne-Kasus-Jacobi@ouhsc.edu


Summary

My lab currently focuses on two research projects that aim at uncovering the molecular mechanisms by which the cationic antimicrobial protein CAP37 is affecting (1) corneal wound healing and (2) neuroinflammation, with the long-term goal of developing peptide therapeutics for ocular injuries and Alzheimer’s disease.

     In collaboration with Dr. Pereira, we found that the antimicrobial and inflammatory mediator CAP37, and several CAP37-derived antimicrobial peptides could promote corneal wound healing andclearance of corneal infections in vivo. Recently, my lab started to focus on the identification of the molecular mechanisms involved in the wound healing activity of CAP37 and CAP37-derived peptides. The goal of this project is the identification of the receptor and intracellular signaling molecules mediating CAP37-induced corneal wound healing.     

     In collaboration with Dr. Pereira, we also explored the potential roles of CAP37 in diseases linked to aging and chronic inflammation. We have shown increased expression of CAP37 in the neurons of patients with Alzheimer’s disease, and an effect of CAP37 on two important players of this disease; amyloid beta and the Receptor for Advanced Glycation End-products (RAGE). To pursue this line of research, my lab is currently exploring the structural aspects of CAP37’s effects on RAGE and amyloid beta. This project, funded by the Oklahoma COBRE in Structural Biology, was started in 2017.



Publications & Presentations

<< 2 3 4 5 6 7 8 > >>
    21. Marchette L D, Thompson D A, Kravtsova M, Ngansop T N, Mandal M N, Kasus-Jacobi A. Retinol dehydrogenase 12 detoxifies 4-hydroxynonenal in photoreceptor cells. Free radical biology & medicine. 2010; 48 : 16-25

    22. Babizhayev M A, Micans P, Guiotto A, Kasus-Jacobi A. N-acetylcarnosine lubricant eyedrops possess all-in-one universal antioxidant protective effects of L-carnosine in aqueous and lipid membrane environments, aldehyde scavenging, and transglycation activities inherent to cataracts: a clinical study of the new vision-saving drug N-acetylcarnosine eyedrop therapy in a database population of over 50,500 patients. American journal of therapeutics. 2009; 16 : 517-33

    23. Mandal M N, Patlolla J M, Zheng L, Agbaga M P, Tran J T, Wicker L, Kasus-Jacobi A, Elliott M H, Rao C V, Anderson R E. Curcumin protects retinal cells from light-and oxidant stress-induced cell death. Free radical biology & medicine. 2009; 46 : 672-9

    24. Babizhayev M A, Guiotto A, Kasus-Jacobi A. N-Acetylcarnosine and histidyl-hydrazide are potent agents for multitargeted ophthalmic therapy of senile cataracts and diabetic ocular complications. Journal of drug targeting. 2009; 17 : 36-63

    25. Babizhayev M A, Kasus-Jacobi A. State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases. Current clinical pharmacology. 2009; 4 : 4-37

<< 2 3 4 5 6 7 8 > >>



Grants

1 2 3 4 >>
    1. STTR Phase 1: Multi-target Peptide Drug for Alzheimer's Disease. NIA. Start Date: 2024. End Date: 2025.

    2. Multitarget Peptide: A Drug to Remember. State Agency. Start Date: 2023. End Date: 2024.

    3. The Midwest Biomedical Accelerator Consortium (MBArC)/ Subaward - Multi-Target Peptide: A Drug to Remember. NHLBI. Start Date: 2021. End Date: 2024.

    4. STTR Phase 1: Novel Ophthalmic Product for Corneal Infections and Injuries. NIH. Start Date: 2021. End Date: 2023.

    5. COP Seed Grant: Characterization of changes in pathogenic amyloid beta aggregation induced by peptide drug candidates for Alzheimer’s disease. Intramural Funding. Start Date: 2022. End Date: 2023.

1 2 3 4 >>



Awards and Honors

1 2 3 >>
                                                                                            1. NIH. MBArC-REACH Second tranche. Date: 2023.  

                                                                                            2. OUHSC College of Pharmacy. Seed Grant. Date: 2022.  

                                                                                            3. OCAST. OCAST-OARS. Date: 2022.  

                                                                                            4. OUHSC/Office of Technology Development. Growth Fund. Date: 2021.  

                                                                                            5. NIH. MBArC-REACH First tranche. Date: 2021.  

1 2 3 >>



Education

                                                                                            1.  Degree: Ph D. University of Paris XI. Date: 1998.  

                                                                                            2.  Degree: MS. University of Paris VII. Date: 1993.  

                                                                                            3.  Degree: BS. University of Paris VII. Date: 1992.  




Administrative Assignments

                                                

    1. Role: Director. Scope: College. Description: Director of Strategic Partnerships and Program Development in the Graduate College.Responsibilities:Develop initiatives to establish scholarship funds for graduate students.Organize education seminars and/or workshops for students. Date: 1969.